332 ENCINITAS BOULEVARD, ENCINITAS, CA
Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model
Kiora Pharmaceuticals Increases Share Allocation by 1.5 Million Shares
Reports First Quarter 2026 Financial Results and Provides Corporate Update
Annual Report to Security Holders
Announces Private Placement for Up to $24 Million led by Perceptive Advisors
Announces Management Team Changes
Financial Results, Press Release
Reports Third Quarter 2025 Results; Advances Pipeline with Two Actively Enrolling Phase 2 Clinical Trials for Retinal Diseases
Q1
FY 2025
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload